Program
Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18
Its studies are led by Suzhou Zelgen Biopharmaceuticals.
Furthest: phase 2, since Oct 10, 20222 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals | 22 open or running | phase 2since Oct 10, 2022 | Oct 10, 2022 | May 2027phase 2 · NCT06938880 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05584800 · 222 planned · China
- Apr 7, 2025Phase 2 study in Advanced Solid TumorNCT06938880 · 60 planned · China
Ahead
- Nov 1, 2026Primary completion: phase 2 study in Advanced Solid TumorNCT05584800
- May 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06938880
TargetBeta
“A bifunctional antibody fusion protein targeting both vascular endothelial growth factor (VEGF) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06938880Advanced Solid Tumor · China | 2 | Recruiting | May 2027 | 60 |
| NCT05584800Advanced Solid Tumor · China | 2 | Recruiting | Nov 1, 2026 | 222 |
How it is read
Names in the registry
- “ZGGS18 for Injection”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.